FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.
Sponsored Content
2022 Economic Forecast: Registration is open!
Presented by BizWest: Thursday, January 27, 2022 from 11 a.m. to 1:30 p.m. at Embassy Suites in Loveland, CO featuring Keynote Speaker Richard L. Wobbekind - Associate Dean for Business & Government Relations, Senior Economist and Faculty Director of the Business Research Division at the University of Colorado Boulder.
The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.
Stratera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year.
“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,” Statera CEO Michael Handley said in a prepared statement.
The company said in August that it’s evaluating or developing 21 drug candidates.
By the end of the quarter, it completed Phase 2 work on a drug for pediatric Crohn’s disease and is setting up Phase 3, to begin in early 2022.
© 2021 BizWest Media LLC
FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB), a pharmaceutical company formed this year from the merger of Cleveland BioLabs Inc. and Cytocom Inc., has provided its first test patient with a dose of its COVID-19 treatment drug candidate STAT-205.
Sponsored Content
Register today for the 2022 Book of Lists Launch Party!
BizWest will unveil the 2022 Book of Lists at a special celebration with businesses that rank at the top of their lists and who are critical to the region’s economic growth. Join us on January 20 at Grace Place in Berthoud for drinks and hors d’oeuvres at the year’s first B2B event. Sponsored by fnbo.
The drug, in preclinical trials, has shown the potential to block the replication of coronaviruses in human lung cells.
Stratera’s randomized, single-blind, placebo-controlled study will enroll 24 adult patients, with preliminary results expected to be reported next year.
“We look forward to working with the researchers to explore the potential of STAT-205 as an oral cost-effective therapeutic option for patients with COVID-19,” Statera CEO Michael Handley said in a prepared statement.
The company said in August that it’s evaluating or developing 21 drug candidates.
By the end of the quarter, it completed Phase 2 work on a drug for pediatric Crohn’s disease and is setting up Phase 3, to begin in early 2022.
© 2021 BizWest Media LLC
…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the ALL NEW Breaking Ground website!
